Organogenesis Holdings (ORGO) Change in Accured Expenses (2016 - 2026)

Organogenesis Holdings' Change in Accured Expenses history runs 11 years deep, the most recent figure standing at $293000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 103.67% year-over-year to $293000.0 in Q1 2026; TTM through Mar 2026 was $18.7 million, a 198.02% increase from a year earlier, with the FY2025 full-year figure at $10.4 million, up 1077.5% from the prior year.
• Change in Accured Expenses fell to $293000.0 in Q1 2026 per ORGO's latest filing, from $8.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $10.0 million in Q1 2024 and bottomed at -$9.9 million in Q2 2024.
• The 5-year median for Change in Accured Expenses is $23000.0 (2023), against an average of -$126294.1.
• Biggest YoY gain for Change in Accured Expenses was 45309.09% in 2024; the steepest drop was 22180.0% in 2024.
• Year by year, Change in Accured Expenses stood at -$7.8 million in 2022, then jumped by 100.3% to $23000.0 in 2023, then plunged by 5065.22% to -$1.1 million in 2024, then jumped by 880.65% to $8.9 million in 2025, then slumped by 96.71% to $293000.0 in 2026.
• Per Business Quant, the three latest ORGO Change in Accured Expenses figures stand at $293000.0 (Q1 2026), $8.9 million (Q4 2025), and $1.4 million (Q3 2025).